You are here
Scheduling delegate's final decisions, October 2017
Scheduling medicines and poisons
2. Summary of delegate’s final decisions
Part A - Final decisions on matters referred to an expert advisory committee
Advisory Committee on Medicines Scheduling (ACMS #21)
|Sildenafil||The current scheduling of sildenafil remains appropriate.|
|Vardenafil||The current scheduling of vardenafil remains appropriate|
|Ibuprofen combined with paracetamol||The current scheduling of ibuprofen combined with paracetamol remains appropriate.|
Schedule 4 – Amend Entry
ESOMEPRAZOLE except when included in Schedule 2.
Schedule 3 – Delete Entry
Schedule 2 – Amend Entry
ESOMEPRAZOLE in oral preparations containing 20 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.
Appendix K – New Entry